| Oct 28 |
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
|
| Oct 24 |
Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week
|
| Oct 24 |
Earnings Preview: Ardelyx (ARDX) Q3 Earnings Expected to Decline
|
| Oct 22 |
Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
|
| Oct 21 |
Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community
|
| Oct 18 |
Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher
|
| Oct 17 |
Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
|
| Oct 15 |
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week
|
| Oct 9 |
Ardelyx Inc (ARDX) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Challenges
|
| Oct 9 |
Even though Ardelyx (NASDAQ:ARDX) has lost US$210m market cap in last 7 days, shareholders are still up 352% over 3 years
|
